Stability of coagulation proteins in frozen plasma.

Serbio (Diagnostica Stago), Gennevilliers, France.
Blood Coagulation and Fibrinolysis (Impact Factor: 1.38). 07/2001; 12(4):229-36. DOI: 10.1097/00001721-200106000-00002
Source: PubMed

ABSTRACT This study reports on the frozen stability of all commonly measured coagulation proteins in normal citrated plasma: activated partial thromboplastin time, prothrombin time (%), thrombin time and fibrinogen (Clauss); clotting assays for factors II, V, VII, VIII, IX, X, XI and XII; functional assays for protein C (clotting), protein S (clotting), antithrombin (chromogenic) and plasminogen (chromogenic); and immunological assays for von Willebrand factor and D-dimer. All these factors listed are stable for up to 3 months if frozen at -24 degrees C or lower. At -74 degrees C, all these factors (allowing for 10% variation) were stable for at least 18 months, most were stable for 24 months. The number of proteins showing > 5% variation over baseline after 6 months storage indicates that some decay does occur even at -74 degrees C. There was no clear advantage in snap freezing at -74 degrees C and then storing at -24 degrees C over both freezing and storing at -24 degrees C; therefore, the freezing process itself is not responsible for the loss of stability. The best stability, especially at -24 degrees C, was obtained when small samples (1 ml) were stored in screw-cap tubes with a minimum dead space. The decrease in stability of the coagulation proteins directly correlates with the effect of temperature and time.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Millions of biological samples are currently kept at low tempertures in cryobanks/biorepositories for long-term storage. The quality of the biospecimen when thawed, however, is not only determined by processing of the biospecimen but the storage conditions as well. The overall objective of this article is to describe the scientific basis for selecting a storage temperature for a biospecimen based on current scientific understanding. To that end, this article reviews some physical basics of the temperature, nucleation, and ice crystal growth present in biological samples stored at low temperatures (-20°C to -196°C), and our current understanding of the role of temperature on the activity of degradative molecules present in biospecimens. The scientific literature relevant to the stability of specific biomarkers in human fluid, cell, and tissue biospecimens is also summarized for the range of temperatures between -20°C to -196°C. These studies demonstrate the importance of storage temperature on the stability of critical biomarkers for fluid, cell, and tissue biospecimens.
    Biopreservation and Biobanking 06/2014; · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fluid biospecimens (blood, serum, urine, saliva, cerebrospinal fluid and bronchial lavage fluid) contain not only cells and subcellular components, but also proteins, enzymes, lipids, metabolites, and peptides, which are utilized as biomarkers. Availability of high-quality biospecimens is a requirement for biomarker discovery. The quality of the biospecimens depends upon preanalytical variables (ie, collection and processing techniques, freeze/thaw stability, and storage stability), which account for >60%-90% of the diagnostic errors. Currently, millions of fluid biospecimens are stored in hundreds of biorepositories across the nation, and tens of thousands of new biospecimens are added to the pool daily. Specimen stabilization is imperative, because fluid biospecimens degrade quickly when kept untreated at room temperature. Achieving a high-quality fluid biospecimen requires understanding the effects of storage processing parameters (eg, freezing and thawing as well as cryo-/lyoprotectant additives) and storage conditions on biomarkers contained within the biospecimens. In this article, we will discuss the main issues related to the stabilization of specific biofluids by reviewing (a) the current preservation and storage practices applied in biobanks/biorepositories and (b) the sensitivity of certain biomarkers to current storage techniques.
    Biopreservation and Biobanking 09/2011; 9(3):237-44. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thyroid hormone affects the coagulation system, but its effect on clinical disease is not clear. We determined the associations between levels of free thyroxine (FT4), thyroid stimulating hormone (TSH) and thyroid peroxidase antibodies (antiTPO) with levels of coagulation factors and the risk of venous thrombosis. In a large population based case-control study (MEGA-study) into the etiology of venous thrombosis we determined levels of FT4, TSH and antiTPO and coagulation factors FII, FVII, FVIII, FIX, FX, VWF, antithrombin, protein C and S, and fibrinogen in 2177 cases and 2826 controls. High levels of FT4 were associated with increased concentrations of procoagulant factors, and not with levels of the anticoagulant factors. High levels of FT4 were also associated with the risk of venous thrombosis, up to an OR of 2.2 (CI95 1.0-4.6) for levels above 24.4 pmol/l relative to FT4 levels between 15.5 and 18.9 pmol/l. In 11 cases and 1 control clinical hyperthyroidism had been diagnosed within a year of the thrombotic event, leading to an OR of 17.0 (CI95 2.2-133.0) for thrombosis. The odds ratios approached unity after adjustment for FVIII and VWF, which suggests that the effect was mediated by these factors. Low TSH levels were also, but less evidently associated with thrombosis, while there was no association with antiTPO and venous thrombosis risk. High levels of FT4 increase the concentrations of procoagulant proteins FVIII, FIX, fibrinogen and VWF and by this mechanism increase the risk of venous thrombosis. This article is protected by copyright. All rights reserved.
    Journal of Thrombosis and Haemostasis 03/2014; · 6.08 Impact Factor